Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009268
Filing Date
2023-05-11
Accepted
2023-05-11 08:01:07
Documents
54
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ewtx-20230331x10q.htm   iXBRL 10-Q 1663994
2 EX-10.1 ewtx-20230331xex10d1.htm EX-10.1 45254
3 EX-10.2 ewtx-20230331xex10d2.htm EX-10.2 89434
4 EX-31.1 ewtx-20230331xex31d1.htm EX-31.1 19401
5 EX-31.2 ewtx-20230331xex31d2.htm EX-31.2 19024
6 EX-32.1 ewtx-20230331xex32d1.htm EX-32.1 7532
7 EX-32.2 ewtx-20230331xex32d2.htm EX-32.2 7609
  Complete submission text file 0001558370-23-009268.txt   5531693

Data Files

Seq Description Document Type Size
8 EX-101.SCH ewtx-20230331.xsd EX-101.SCH 30769
9 EX-101.CAL ewtx-20230331_cal.xml EX-101.CAL 36681
10 EX-101.DEF ewtx-20230331_def.xml EX-101.DEF 119297
11 EX-101.LAB ewtx-20230331_lab.xml EX-101.LAB 314455
12 EX-101.PRE ewtx-20230331_pre.xml EX-101.PRE 225378
48 EXTRACTED XBRL INSTANCE DOCUMENT ewtx-20230331x10q_htm.xml XML 759300
Mailing Address 1715 38TH ST BOULDER CO 80301
Business Address 1715 38TH ST BOULDER CO 80301 720-262-7002
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

EIN.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40236 | Film No.: 23908927
SIC: 2834 Pharmaceutical Preparations